Thank you to everyone who joined us at the AAAAI Foundation’s Annual Benefit and the 14th Anniversary Run/Walk Celebration in Philadelphia. We hope to see you again next year in New Orleans!

#AAAAI26 #AAAAI27

Remibrutinib Shows Rapid Symptom Relief in CSU, With Mark Lebwohl, MD | HCPLive At AAAAI 2026, Lebwohl discussed REMIX trial data showing oral remibrutinib reduced CSU symptoms within 12 hours and improved disease control.

Phase 3 REMIX trial data presented at #AAAAI26 show the oral BTK inhibitor remibrutinib reduced #CSU within 12 hours. Check out our interview with investigator Mark G. Lebwohl @MountSinaiNYC, here:

Phase 2 data at #AAAAI26 suggest BW-20805 may offer long-acting prophylaxis for #HAE. In interim analysis, attack rates fell up to 100% with dosing intervals as long as 6 months. Markus Magerl, MD, breaks down findings: www.hcplive.com/view...

How Young Should Food Allergy Treatment Start? Experts parse evidence for an early start

"They don't want to sit on their hands and do nothing for the kids." -- Wayne Shreffler, MD, PhD, of Massachusetts General Hospital, on how parents are eager to seek early intervention after a #foodallergy diagnosis. @aaaaiorg.bsky.social #AAAAI26
www.medpagetoday.com/meetingcover...

Navenibart at 3- and 6-Month Dosing Reduces HAE Attacks, With Adil Adatia, MD | HCPLive Phase 2 ALPHA-SOLAR data presented at AAAAI 2026 show navenibart provides >95% median attack reduction in HAE with favorable safety for 3- and 6-month prophylaxis.

Phase 2 ALPHA-SOLAR data presented at #AAAAI26 show navenibart given every 3 or 6 months reduced #HAE attacks by > 95%. Adil Adatia, MD, discusses how this long-acting kallikrein inhibitor may lower treatment burden:

Didn't get a chance to pick up your clinic posters on Asthma Inhalers and Easy-to-Use Epinephrine Options at the #AAAAI26 Annual Meeting? You can still download them!

#AsthmaInhaler poster:
aafa.org/wp-content/u...

#Epinephrine Options poster: kidswithfoodallergies.org/wp-content/u...

#HCP

Didn't get a chance to pick up your clinic posters on Asthma Inhalers and Easy-to-Use Epinephrine Options at the #AAAAI26 Annual Meeting? You can still download them!

#AsthmaInhaler poster:
aafa.org/wp-content/u...

#Epinephrine Options poster: kidswithfoodallergies.org/wp-content/u...

#HCP

Thank you to everyone who made the 2026 AAAAI Annual Meeting such a success. We can’t wait to do it again next year! Stay tuned for more updates.

#AAAAI26

#Sponsored by: @Genentech

Tune in to #FAACTsRoundtable Podcast about Updates from @AAAAI_org and @WorldAllergy Organization (WAO) Joint Congress

Listen to #FAACT's Ep. 271:
www.buzzsprout.com/848314/episo...

#AAAAI26 #FoodAllergy #FoodAllergeries #Research #Anaphylaxis #Allergy #Asthma #Podcast

Dupilumab Reduces GI Symptoms During Multi-Allergen OIT, With Sayantani Sindher, MD | HCPLive COMBINE trial data show dupilumab added to omalizumab-assisted OIT improved desensitization and reduced GI symptoms, despite no sustained response benefit.

Dupilumab reduced GI symptoms and improved desensitization when added to omalizumab-assisted multi-allergen #OIT in the COMBINE trial. Watch #AAAAI26 interview with Sayantani Sindher, MD, @Stanford: www.hcplive.com/view... #allergy

#FAACT's March e-Newsletter Is Out!

1. New Research from #AAAAI26
2. Start Planning for #FoodAllergyAwareness Month
3. Register for FAACT's Strides for Safety 5K in Cincinnati
4. Registration Is Open for FAACT's #Allergy Summit

And much more...

Read our March e-NL here:
mailchi.mp/foodallergya...

Cem Akin, MD, @umichmedschool discussed the importance of understanding the symptom burden in mastocytosis and the potential for bezuclastinib to improve outcomes at #AAAAI26 . Watch now: www.hcplive.com/view...

A noteworthy highlight of #AAAAI26 was connecting with @aafanational.bsky.social 🌟 As longtime collaborators, we’re proud to advance patient-centered education in #asthma & #allergy care together, delivering education that empowers patients & strengthens clinical decision-making. 💜 bit.ly/478yEQC

American Academy of Allergy, Asthma & Immunology Archives Presenting research from the annual meeting of the American Academy of Allergy, Asthma & Immunology.

Catch up with all the most important research presented at #AAAAI26 on our dedicated AAAAI conference page www.empr.com/conferences/...

Second Biologic Might Improve Tolerability of Multi-Food Allergy Immunotherapy Phase II data suggest fewer GI adverse effects when given a sequence of biologics

For multi-allergen oral immunotherapy patients, adding dupilumab (Dupixent) after omalizumab (Xolair) showed promise for cutting the gastrointestinal adverse events of ongoing mOIT, although perhaps not its efficacy, the phase II COMBINE trial showed. #AAAAI26
www.medpagetoday.com/meetingcover...

BTK Inhibitor Shows Promise for Food Allergy Treatment Phase II data suggest remibrutinib could compete with approved injectable

Oral remibrutinib (Rhapsido) increased peanut tolerance in adults with proven allergy to it, with benefits in as little as 1 week, a phase II trial showed. #AAAAI26
www.medpagetoday.com/meetingcover...

Immunotherapy Skin Patch Tames Peanut Allergy Reactions in Kids Will new phase III trial finally be the golden ticket with the FDA?

Peanut allergy immunotherapy delivered by an investigational skin patch increased the proportion of children ages 4 to 7 years who could tolerate a dose of peanut protein in the phase III VITESSE trial. #AAAAI26
www.medpagetoday.com/meetingcover...

Tree Nut Introduction Not Better in Office Than at Home for Peanut-Allergic Babies Randomized trial finds no benefit for safety or tree nut allergy rates

For peanut-allergic babies, introducing tree nuts all at once in-clinic wasn't superior to doing so at home gradually, the TrEat trial showed. #AAAAI26
www.medpagetoday.com/meetingcover...

Biologic on Par With OIT for Turning Allergy-Forbidden Foods Into Everyday Eats Final stage of the OUtMATCH trial tracks outcomes for oral immunotherapy versus omalizumab alone

Most multi-food allergic children succeeded in longer term regular dietary consumption whether treated with oral immunotherapy or omalizumab (Xolair) alone, results from stage 3 of the OUtMATCH trial showed. #AAAAI26
www.medpagetoday.com/meetingcover...

#AAAAI26 round-up ⬇️

Check out our coverage from this year's @aaaaiorg.bsky.social meeting 👀

What an incredible week at #AAAAI26! Don't forget to claim your CME credits. Visit the Annual Meeting website to get started. https://annualmeeting.aaaai.org/

The team is onsite at #AAAAI26 this week & what an incredible few days it’s been connecting with APFED, I-FPIES, NEA, @faactnews.bsky.social, & others. 👏 Conversations centered on patient needs, education gaps, & elevating evidence-based resources for all. Explore our collaborations: bit.ly/3OIxu8c

What an amazing time in Philadelphia! Thank you to all who joined us at #AAAAI26. Until next year, keep advancing the field of allergy, asthma and immunology!

With the meeting coming to a close soon, we wish you a safe trip home. Looking forward to seeing you next year! #AAAAI26

The interactive workshops at #AAAAI26 have been incredible, with hands-on skills, small group discussions and practical takeaways you can use with your patients immediately.

Final day of #AAAAI26! Today's plenary is Multiomics in Asthma: Incredible Progress at Breakneck Speed. Don’t miss it!

Day three of the Annual Meeting has concluded! We will see everyone for the final day on Monday. #AAAAI26

Plan on heading to the Monday Plenary tomorrow. #AAAAI26

Join us for the AAAAI Foundation's Run/Walk Celebration! As part of this year’s event, we’ll celebrate 14 years of the Run/Walk with food, music, awards, networking opportunities and a photo slideshow. #AAAAI26

Celebrate Our Year and Learn What’s to Come at tomorrow's AAAAI Business Meeting. #AAAAI26